You are here: Home / Protocols / Biomarkers for Prostate and Bladder Cancer

Biomarkers for Prostate and Bladder Cancer

114
Liu, Alvin Y.University of Washington
Liu, Alvin Y.University of Washington
CD90, AGR2, CEACAM5
Genomics
Proteomics
Prostate and Urologic Cancers Research Group

CD26+ cancer cells and CD90+ tumor-associated stromal cells were sorted from tumor tissue. Dataset analysis with transcriptomes of CD26+ luminal, CD104+ basal, CD49a+ stromal and CD31+ endothelial was carried out to identify candidates: CD90, AGR2, BCMP11, CEACAM5, CRISP3. Quantitative protomics was applied to measure these proteins in urine samples.

Sort cancer cells from tumor specimens Determine gene expression (transcriptome) by Affymetrix DNA arrays Dataset analysis to identify cancer up-regulated genes encoding secreted or extracellular proteins Proteomic analysis (mass spectrometry, Western blotting) to validate increased cancer expression
Genomics and proteomics. DNA microarray analysis of sorted cell types to identify cancer-specific genes encoding secreted/extracellular proteins. Mass spectrometry-based proteomics to measure protin levels in case vs. control urine samples.
Data analysis was done to evaluate data quality of Affymetrix arrays (mRNA expression correlation to protein expression by immunohistochemistry), to compare other publicly available prostate cancer datasets.

Announcement 09/27/2019
Thank you to everyone who made the 11th EDRN Scientific Workshop a success. The next EDRN Steering Committee Meeting is from Tuesday-Thursday, March 31-April 2, 2020 in Tempe, AZ.
Announcement



 
This icon signifies that something is happening and we kindly ask you to please wait